Advanced directives are not yet sufficiently widespread in France, especially on the situation of people with Alzheimer’s disease or related illnesses. The participative aspect of the decision-making process is therefore often lacking in such complex clinical cases, and must be adapted to the hierarchical relationships within the team, which tends to limit the ability of nursing care professionals to express themselves in front of the clinician. To address this essential matter in research, Inhibitors,research,lifescience,medical the analysis of ongoing clinical situations seems to us the most pragmatic approach. Sharing the different practical

experiences of numerous teams concerning dementia patients at the

end of life may help to establish markers for strengthening the decision to introduce or withhold, withdraw or continue Inhibitors,research,lifescience,medical treatment for an acute complication. Methods/design This is a cross sectional multicentre study of clinical cases concerning all medical and medico-social institutions admitting people with advanced dementia, in an area with a population of 2.2 million in the east of France (Burgundy and Franche-Comté). Of the 92 institutions contacted, 67 Inhibitors,research,lifescience,medical (72.8%) responded favourably to our request (University hospitals, general hospitals, local hospitals and homes for the elderly). The protocol was approved by the clinical ethics committee of Besançon University Hospital. This study was funded

by the National Clinical Research Programme (PHRC) of the French Ministry of Health. Each department Inhibitors,research,lifescience,medical was invited to consider all eligible patients suffering from advanced dementia of the Alzheimer type presumed to be at the end of life (ICG-001 price presenting with cachexia and more rapid change in their general state over the last three months) and presenting with acute Inhibitors,research,lifescience,medical complications which may endanger life and challenge the relevance of continuing, changing or withdrawing, introducing or not introducing a treatment likely to alter survival: organic Resveratrol or systemic infection resisting a first line treatment; occurrence of probable pulmonary embolism; pending stroke; phase IV obliterating arteriopathy of the lower limbs usually requiring deobstruction, a bypass or an amputation; heart failure occurring in treated congestive heart failure; acute kidney failure; respiratory decompensation occurring in treated respiratory failure; signs of appearance or progression of cancer. The study concerned the patients present in the departments and those who had died in the two months prior to the study.